{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:14:37Z","timestamp":1747156477214,"version":"3.40.5"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bpg.2024.101889","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T15:37:47Z","timestamp":1706888267000},"page":"101889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multimodal management of foregut neuroendocrine neoplasms"],"prefix":"10.1016","volume":"68","author":[{"given":"Yichan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Weiquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-9272","authenticated-orcid":false,"given":"Noriya","family":"Uedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.bpg.2024.101889_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"29","key":"10.1016\/j.bpg.2024.101889_bib3","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.2174\/0929867327666200207120725","article-title":"Clinical and Translational research challenges in neuroendocrine tumours","volume":"27","author":"Barriuso","year":"2020","journal-title":"Curr Med Chem"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13100","article-title":"ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology","volume":"34","author":"van Velthuysen","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2019","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.7150\/jca.29483","article-title":"A 10-year Population-based study of the differences between NECs and carcinomas of the esophagus in terms of clinicopathology and survival","volume":"10","author":"Cai","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.bpg.2024.101889_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2019.02.012","article-title":"A rare rarity: neuroendocrine tumor of the esophagus","volume":"137","author":"Giannetta","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.32074\/1591-951X-229","article-title":"Neuroendocrine neoplasms of the esophagus and stomach","volume":"113","author":"Mastracci","year":"2021","journal-title":"Pathologica"},{"issue":"7","key":"10.1016\/j.bpg.2024.101889_bib9","first-page":"10668","article-title":"Turning left or right? A comparative analysis in adenocarcinomas of the esophagogastric junction according to the seventh AJCC TNM classification for cancers of the esophagus and stomach: experience in a Chinese single institution","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"24","key":"10.1016\/j.bpg.2024.101889_bib10","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3748\/wjg.v10.i24.3680","article-title":"Primary small cell carcinoma of esophagus: report of 9 cases and review of literature","volume":"10","author":"Wu","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/SLA.0b013e31824beb95","article-title":"Should adenocarcinoma of the esophagogastric junction Be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification","volume":"255","author":"Suh","year":"2012","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib12","first-page":"68","article-title":"Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients","volume":"54","author":"Putzer","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.bpg.2024.101889_bib13","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.12998\/wjcc.v10.i10.3164","article-title":"Endoscopic submucosal dissection combined with adjuvant chemotherapy for early-stage neuroendocrine carcinoma of the esophagus: a case report","volume":"10","author":"Tang","year":"2022","journal-title":"World Journal of Clinical Cases"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/den.13678","article-title":"Case of esophageal superficial neuroendocrine carcinoma suggestive of transformation from squamous cell carcinoma","volume":"32","author":"Iwagami","year":"2020","journal-title":"Dig Endosc"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12328-022-01595-8","article-title":"A case of endoscopic submucosal dissection for neuroendocrine carcinoma of the esophagus with invasion to the muscularis mucosae","volume":"15","author":"Fukui","year":"2022","journal-title":"Clin J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s10388-023-01003-1","article-title":"Clinical predictors of special type of esophageal cancer","volume":"20","author":"Suzuki","year":"2023","journal-title":"Esophagus"},{"issue":"7","key":"10.1016\/j.bpg.2024.101889_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s10147-020-01631-y","article-title":"Treatment strategies for neuroendocrine carcinoma of the upper digestive tract","volume":"25","author":"Morita","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1442-2050.2009.01045.x","article-title":"Original article: surgical management for small cell carcinoma of the esophagus","volume":"23","author":"Tanaka","year":"2010","journal-title":"Dis Esophagus"},{"issue":"12","key":"10.1016\/j.bpg.2024.101889_bib20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2169\/internalmedicine.2151-18","article-title":"Early-stage neuroendocrine carcinoma of the esophagus observed with annual endoscopy for three years","volume":"58","author":"Tanaka","year":"2019","journal-title":"Internal Medicine"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Delle Fave","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.bpg.2024.101889_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12022-014-9315-x","article-title":"Neuroendocrine pathology of the stomach: the Parma contribution","volume":"25","author":"Bordi","year":"2014","journal-title":"Endocr Pathol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1590\/0102-6720201700020016","article-title":"Gastric neuroendocrine tumor: review and update","volume":"30","author":"Dias","year":"2017","journal-title":"ABCD. Arquivos Brasileiros de Cirurgia Digestiva (S\u00e3o Paulo)"},{"year":"2021","series-title":"Changing biological behaviour of NETs during the evolution of the disease progress on progression","author":"Krystallenia","key":"10.1016\/j.bpg.2024.101889_bib25"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.gie.2019.06.029","article-title":"Enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction","volume":"90","author":"Ishioka","year":"2019","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"10.1016\/j.bpg.2024.101889_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.dld.2021.11.012","article-title":"Management of type-I gastric neuroendocrine neoplasms: a 10-years prospective single centre study","volume":"54","author":"Esposito","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib28","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.dld.2015.07.155","article-title":"Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis","volume":"47","author":"Massironi","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib29","doi-asserted-by":"crossref","DOI":"10.5946\/ce.2015.48.5.431","article-title":"Multicentric type 3 gastric neuroendocrine tumors","volume":"48","author":"Lee","year":"2015","journal-title":"Clinical Endoscopy"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10120-022-01277-x","article-title":"A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy","volume":"25","author":"Zhu","year":"2022","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10120-013-0281-7","article-title":"Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis","volume":"17","author":"Domori","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bpg.2024.101889_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.106987","article-title":"Molecular profiling of gastric neuroendocrine carcinomas","author":"Ikegame","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2024.101889_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/a-1751-5742","article-title":"Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"54","author":"Deprez","year":"2022","journal-title":"Endoscopy"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12020-022-03143-3","article-title":"Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter","volume":"78","author":"Exarchou","year":"2022","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.bpg.2024.101889_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MEG.0000000000000566","article-title":"Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging","volume":"28","author":"Lahner","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2024.101889_bib36","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.bpg.2024.101889_bib37","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.dld.2016.07.001","article-title":"Type 3 gastric neuroendocrine tumor with unique endoscopic features","volume":"48","author":"Kawasaki","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2024.101889_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.16309","article-title":"Endoscopic features of gastric neuroendocrine carcinoma","author":"Matsueda","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10120-011-0025-5","article-title":"Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma","volume":"14","author":"Okita","year":"2011","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s101470200018","article-title":"A patient with small-cell carcinoma of the stomach with long survival after percutaneous microwave coagulating therapy (PMCT) for liver metastasis","volume":"7","author":"Tanemura","year":"2002","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2024.101889_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/RLU.0000000000002961","article-title":"The complementary role of 68Ga-DOTATATE PET\/CT in Neuroblastoma","volume":"45","author":"Telli","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.bpg.2024.101889_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6679397","article-title":"Comparison of endoscopic techniques in the management of type I gastric neuroendocrine neoplasia: a systematic review","volume":"2021","author":"Panzuto","year":"2021","journal-title":"Gastroenterology Research and Practice"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13105","article-title":"ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors","volume":"34","author":"Borbath","year":"2022","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib44","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/den.14529","article-title":"Clinical characteristics and long-term prognosis of type 1 gastric neuroendocrine tumors in a large Japanese national cohort","volume":"35","author":"Namikawa","year":"2023","journal-title":"Dig Endosc"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/den.12197","article-title":"Management and clinical outcomes of typeIgastric carcinoid patients:Retrospective, multicenter study inJapan","volume":"26","author":"Sato","year":"2013","journal-title":"Dig Endosc"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030872","article-title":"Chronic treatment with somatostatin analogues in recurrent type 1 gastric neuroendocrine tumors","volume":"11","author":"Sebastian-Valles","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/den.13778","article-title":"Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study","volume":"33","author":"Hirasawa","year":"2020","journal-title":"Dig Endosc"},{"issue":"8","key":"10.1016\/j.bpg.2024.101889_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.bpg.2024.101889_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/3658334","article-title":"Clinicopathological features and postoperative survival analysis of gastric carcinoma with neuroendocrine differentiation","volume":"2022","author":"Liu","year":"2022","journal-title":"Journal of Oncology"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000348832","article-title":"Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science","volume":"98","author":"Giandomenico","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-020-01348-2","article-title":"The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual disease","volume":"20","author":"Malczewska","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib53","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.annonc.2021.08.1746","article-title":"A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility","volume":"32","author":"Modlin","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib54","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.annonc.2021.08.1746","article-title":"A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility","volume":"32","author":"Modlin","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib55","doi-asserted-by":"crossref","first-page":"E1437","DOI":"10.1210\/jc.2015-2792","article-title":"Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy","volume":"100","author":"\u0106wik\u0142a","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"issue":"9","key":"10.1016\/j.bpg.2024.101889_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093106","article-title":"Magnifying endoscopy with narrow-band imaging for duodenal neuroendocrine tumors","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"issue":"18","key":"10.1016\/j.bpg.2024.101889_bib57","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.surg.2015.03.042","article-title":"Increasing incidence of duodenal neuroendocrine tumors: incidental discovery of indolent disease?","volume":"158","author":"Fitzgerald","year":"2015","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib59","doi-asserted-by":"crossref","first-page":"818","DOI":"10.5946\/ce.2020.296","article-title":"The role of endoscopy in small bowel neuroendocrine tumors","volume":"54","author":"Yoon","year":"2021","journal-title":"Clin Endosc"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19738-9","article-title":"Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study","volume":"12","author":"Mandair","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11605-021-05133-8","article-title":"Outcomes of endoscopic submucosal dissection in duodenal neuroendocrine tumors","volume":"26","author":"Nabi","year":"2022","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"10.1016\/j.bpg.2024.101889_bib62","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/jgh.15419","article-title":"Gastrointestinal: endoscopic resection with an over-the-scope clip for a duodenal neuroendocrine tumor in a difficult-to-reach location","volume":"36","author":"Tashima","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00464-009-0574-4","article-title":"Minimally invasive surgery for resection of duodenal carcinoid tumors: endoscopic full-thickness resection under laparoscopic observation","volume":"24","author":"Tsujimoto","year":"2010","journal-title":"Surg Endosc"},{"issue":"7","key":"10.1016\/j.bpg.2024.101889_bib64","first-page":"1835","article-title":"Laparoscopic endoscopic cooperative surgery for the duodenal neuroendocrine tumor: a single-center case series (How I Do It)","volume":"109","author":"Guo","year":"2023","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.bpg.2024.101889_bib65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.vgie.2021.12.013","article-title":"Endoscopic full-thickness resection of well-differentiated T2 neuroendocrine tumors in the duodenal bulb: a case series","volume":"7","author":"Dwyer","year":"2022","journal-title":"Video"},{"issue":"8","key":"10.1016\/j.bpg.2024.101889_bib66","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s11605-017-3448-4","article-title":"Duodenal and ampullary carcinoid tumors: size predicts necessity for lymphadenectomy","volume":"21","author":"Dogeas","year":"2017","journal-title":"J Gastrointest Surg"},{"issue":"13","key":"10.1016\/j.bpg.2024.101889_bib67","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1245\/s10434-021-10371-w","article-title":"Ampullary neuroendocrine tumors: insight into a rare histology","volume":"28","author":"Ruff","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.bpg.2024.101889_bib69","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib70","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review","volume":"21","author":"Broder","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"16","key":"10.1016\/j.bpg.2024.101889_bib71","first-page":"1556","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.bpg.2024.101889_bib72","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.bpg.2024.101889_bib74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"10022","key":"10.1016\/j.bpg.2024.101889_bib75","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.bpg.2024.101889_bib76","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10022","key":"10.1016\/j.bpg.2024.101889_bib77","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib78","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib79","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.bpg.2024.101889_bib80","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2024.101889_bib81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","article-title":"Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause?","volume":"44","author":"Lamarca","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.bpg.2024.101889_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.bpg.2024.101889_bib83","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.bpg.2024.101889_bib84","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bpg.2024.101889_bib85","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J Clin Oncol"},{"issue":"6349","key":"10.1016\/j.bpg.2024.101889_bib86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib87","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","article-title":"Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury","volume":"36","author":"Bhagat","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.bpg.2024.101889_bib88","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"10.1016\/j.bpg.2024.101889_bib89","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2024.101889_bib90","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jhbp.1101","article-title":"Safety and response after peptide receptor radionuclide therapy with (177) Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial","volume":"29","author":"Kudo","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib91","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine tumor therapy: (177)Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.bpg.2024.101889_bib92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691824000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691824000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T04:54:26Z","timestamp":1711774466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691824000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":92,"alternative-id":["S1521691824000088"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2024.101889","relation":{},"ISSN":["1521-6918"],"issn-type":[{"type":"print","value":"1521-6918"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal management of foregut neuroendocrine neoplasms","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2024.101889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101889"}}